A -- RESEARCH AND EXPERIMENTS ON DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS

Notice Date

July 2, 2001

Contracting Office

National Hansen's Disease Program, DHHS, Attn: General Services Office, 1770 Physicans Park Drive, Baton Rouge, La 70816-3222

ZIP Code

70816-3222

Solicitation Number

NHDP-01-R-0004

Point of Contact

Suzanne Shumate, 225-756-3787 (Voice), 225-756-3786 (FAX)

E-Mail Address

Click here to contact the Contracting Officer via (sshumate@hrsa.gov)

Description

The National Hansen's Disease Programs (NHDP) intends to negotiate on a sole source basis with the University of Illinois, Chicago (UIC) to contract for the study of anti-Mycobacterium tuberculosis drug development for a one year period beginning September 21, 2001 with four options through June 30, 2006. The major focus is to provide results which can lead to treatment or eradication of M. tuberculosis infection. The purpose of this contract is for UIC to improve, standardize and adopt new assays for determining the activity of compounds against dormant (slowly growing, persistence, or quiescent) M. tuberculosis organisms and to standardize and adopt new assays, as approved by the project officer, to increase testing efficiency and to employ the latest technological developments. A determination for use of other than a full and open competition has been made in accordance with 42 U.S.C. 253(c) (1) as set forth in FAR 6.302-1. UIC has the prerequisite knowledge and experience for this contract because Dr. Scott Franzblau, Director, Institute for TB Research, UIC College of Pharmacy, has served as Principal Investigator on this effort for the period 1995 -- 1999 and also during an extension year (1999 to 2000). During these intervals Dr. Franzblau directed the entire project, which in addition to the two work statements cited above, included cultivation of virulent M. tuberculosis H37Rv and single drug resistant strains of M. tuberculosis, primary evaluation of anti-M. tuberculosis efficacy of >40,000 test compounds, determination of the minimum inhibitory concentrations, minimum bactericidal concentrations, post antibiotic effect, efficacy of test compounds against single drug resistant strains of M. tuberculosis, determination of cytotoxicity and the intracellular activity of test compounds in macrophages, evaluation of test compounds in an in vitro assay for latent tuberculosis and development of a cost effective, high throughput screening assay. All responsible sources may submit a proposal which will be considered by the NHDP. A determination not to compete the proposed work based on responses to this notice is solely within the discretion of the Contracting Officer. This notice of intent is not an announcement of the availability of a Request for Proposals (RFP) nor is an RFP available. See Numbered Note 22.

Record

Loren Data Corp. 20010705/ASOL015.HTM (W-183 SN50Q665)